GlassScriptPhysician profile
Ha Yeon Shin
NPI 1497216360
$3,105.89
in general payments reported to CMS, 2019-2025
23 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.01 · 2023: $55.47 · 2024: $829 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,092.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $541.85 | 2024-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $390.06 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $301.81 | 2025 | Dupixent |
| Blueprint Medicines Corporation | $246.83 | 2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $209.18 | 2024-2025 | |
| Csl Behring | $174.25 | 2024-2025 | Hizentra, Andembry, Privigen |
| Novartis Pharmaceuticals Corporation | $150.55 | 2024-2025 | |
| Organon LLC | $150.00 | 2025 | Vtama |
| Incyte Corporation | $147.87 | 2025 | Opzelura, Opzelura |
| Kaleo, INC. | $130.68 | 2023-2024 | Auvi-Q |
| Leo Pharma INC. | $128.43 | 2025 | Anzupgo, Adbry |
| Grifols USA, LLC | $92.26 | 2023-2025 | Xembify |
| Genzyme Corporation | $88.92 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $72.67 | 2025 | Neffy |
| Amgen INC. | $54.87 | 2024 | Actimmune |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $47.74 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.69 | 2024-2025 | Cuvitru, Eohilia |
| Ionis Pharmaceuticals, INC. | $29.57 | 2025 | Dawnzera |
| Alk-Abello, INC | $27.19 | 2025 | Grastek, Ragwitek, Odactra |
| Pharming Healthcare, INC. | $25.10 | 2025 | Ruconest |
| Phadia US INC. | $21.11 | 2025 | Immunocap |
| Genentech USA, INC. | $18.25 | 2025 | Xolair |
| Merck Sharp & Dohme LLC | $13.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ha Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.